Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Market Cap	13.31B -6.2%
Revenue (ttm)	1.01B +19.1%
Net Income	520.90M +104.8%
EPS	5.89 +106.3%
Shares Out	87.60M
PE Ratio	25.79
Forward PE	26.12
Dividend	4.65 (3.06%)
Ex-Dividend Date	Apr 30, 2025

Volume	763,664
Average Volume	312,871
Open	161.00
Previous Close	152.00
Day's Range	154.00 - 161.00
52-Week Range	130.46 - 188.00
Beta	0.37
RSI	39.48
Earnings Date	Mar 31, 2026

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine (ADCV01), a drug candidate in Phase II clinical trials for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6712

Financial Performance

In 2024, TPEX:6712's revenue was 933.81 million, an increase of 23.13% compared to the previous year's 758.39 million. Earnings were 367.25 million, a decrease of -31.91%.